6533b828fe1ef96bd128797c
RESEARCH PRODUCT
Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron : The Myocardial- Trial
Luis AlmenarMaría Del Carmen MorenoJulio NúñezJulio NúñezJorge A. R. NavarroGema MiñanaGema MiñanaPau LlàcerMartina AmiguetJessika GonzálezFrancisco J. ChorroFrancisco J. ChorroLorenzo FácilaAnna MollarVicente MontagudRaquel López-vilellaMaria Pilar López‐lereuJose CiveraRafael De La EspriellaErnesto ValeroErnesto ValeroJose V. MonmeneuPatricia PalauAntoni Bayes-genisAntoni Bayes-genisJosep Comín-coletVerónica VidalIngrid CardellsAlicia SerranoMeritxell SolerJosep LupónJosep LupónSergio García-blasSergio García-blasVicent BodíVicent BodíJosé Luis GórrizJuan SanchisJuan SanchisAmparo Villaescusasubject
MaleCardiac magnetic resonance*ferric carboxymaltoseMagnetic Resonance Imaging (MRI)Myocardial ironAnèmia*heart failure030204 cardiovascular system & hematologyFerric Compounds0302 clinical medicine030212 general & internal medicineOriginal Researchcardiac magnetic resonance ferric carboxymaltose heart failure iron deficiency myocardial ironAnemia Iron-DeficiencyAnemiaIron deficiencyMiddle AgedMyocardial ironMagnetic Resonance Imaging*myocardial ironMagnetic resonanceCardiologyAdministration IntravenousFemaleCardiology and Cardiovascular Medicine*cardiac magnetic resonancemedicine.medical_specialtyNoninvasive imagingCardiomyopathyIronIntravenous ironHeart failureFERRIC CARBOXYMALTOSE03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltoseAgedPharmacologybusiness.industryMyocardiumIron deficiencyRessonància magnèticaMiocardimedicine.diseaseFerric carboxymaltoseTreatmentHeart failureHematinicsbusinessCardiac magnetic resonance*iron deficiencyFerrodescription
Background Intravenous ferric carboxymaltose ( FCM ) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Methods and Results Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least‐square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65–78) years, with N‐terminal pro‐B‐type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010–2828), 63 ng/mL (22–114), and 15.7% (11.0–19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the FCM arm (36.6 [34.6–38.7] versus 40 [38–42.1], P =0.025; 1061 [1051–1072] versus 1085 [1074–1095], P =0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1–38.5] versus 41.1 [38.9–43.4], P =0.003), but not for T1 mapping (1075 [1065–1085] versus 1079 [1069–1089], P =0.577). Conclusions In patients with heart failure and iron deficiency, FCM administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 03398681.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-02-13 |